X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs STERLING BIOTECH - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA STERLING BIOTECH SUN PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 39.0 -0.7 - View Chart
P/BV x 3.0 0.0 10,554.4% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 SUN PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
STERLING BIOTECH
Dec-13
SUN PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs84211 8,020.0%   
Low Rs5723 16,835.3%   
Sales per share (Unadj.) Rs131.626.8 491.0%  
Earnings per share (Unadj.) Rs32.7-15.0 -218.6%  
Cash flow per share (Unadj.) Rs38.0-5.5 -695.1%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs152.754.9 278.3%  
Shares outstanding (eoy) m2,399.26267.87 895.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.40.3 2,072.6%   
Avg P/E ratio x21.6-0.5 -4,654.2%  
P/CF ratio (eoy) x18.6-1.3 -1,463.9%  
Price / Book Value ratio x4.60.1 3,657.2%  
Dividend payout %10.70-   
Avg Mkt Cap Rs m1,696,8771,862 91,146.7%   
No. of employees `00017.51.4 1,293.6%   
Total wages/salary Rs m49,023547 8,965.4%   
Avg. sales/employee Rs Th18,028.35,303.3 339.9%   
Avg. wages/employee Rs Th2,798.8403.8 693.0%   
Avg. net profit/employee Rs Th4,479.5-2,959.0 -151.4%   
INCOME DATA
Net Sales Rs m315,7847,181 4,397.7%  
Other income Rs m6,23243 14,627.9%   
Total revenues Rs m322,0167,223 4,458.0%   
Gross profit Rs m100,893947 10,655.1%  
Depreciation Rs m12,6482,543 497.3%   
Interest Rs m3,9984,377 91.3%   
Profit before tax Rs m90,479-5,931 -1,525.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,116-1,924 -629.6%   
Profit after tax Rs m78,462-4,007 -1,958.4%  
Gross profit margin %31.913.2 242.3%  
Effective tax rate %13.432.4 41.3%   
Net profit margin %24.8-55.8 -44.5%  
BALANCE SHEET DATA
Current assets Rs m329,53714,335 2,298.8%   
Current liabilities Rs m178,87049,809 359.1%   
Net working cap to sales %47.7-494.0 -9.7%  
Current ratio x1.80.3 640.1%  
Inventory Days Days79403 19.6%  
Debtors Days Days83171 48.8%  
Net fixed assets Rs m204,76655,432 369.4%   
Share capital Rs m2,399268 895.6%   
"Free" reserves Rs m363,99713,935 2,612.1%   
Net worth Rs m366,39714,701 2,492.3%   
Long term debt Rs m14,3619,478 151.5%   
Total assets Rs m614,10273,988 830.0%  
Interest coverage x23.6-0.4 -6,657.3%   
Debt to equity ratio x00.6 6.1%  
Sales to assets ratio x0.50.1 529.8%   
Return on assets %13.40.5 2,680.8%  
Return on equity %21.4-27.3 -78.6%  
Return on capital %24.8-6.4 -386.5%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m44,1181,860 2,372.2%   
Fx outflow Rs m24,48425 98,369.2%   
Net fx Rs m19,6341,835 1,070.0%   
CASH FLOW
From Operations Rs m70,8221,719 4,120.7%  
From Investments Rs m-42,216-3,148 1,341.0%  
From Financial Activity Rs m-22,8541,426 -1,602.7%  
Net Cashflow Rs m6,107-3 -179,608.8%  

Share Holding

Indian Promoters % 63.7 33.9 187.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.0 -  
FIIs % 23.0 9.9 232.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 8.3 39.3 21.1%  
Shareholders   133,026 21,482 619.2%  
Pledged promoter(s) holding % 0.5 55.9 0.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   FULFORD INDIA  VENUS REMEDIES  PIRAMAL ENTERPRISES  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; SBI Up 3.7%(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


May 23, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS